Trials / Recruiting
RecruitingNCT05882175
Prospective Validation of the OHI Index
A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Meir Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
Detailed description
The investigators will enroll patients with new/transformed hematologic malignancies. The investigators will follow the patients until the end of the study, report their survival at one year and examine their prognosis.
Conditions
- HLH
- Hemophagocytic Lymphohistiocytoses
- Hemophagocytic Syndrome
- Hematologic Malignancy
- Hematologic Neoplasms
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2030-03-03
- Completion
- 2030-03-03
- First posted
- 2023-05-31
- Last updated
- 2025-05-13
Locations
2 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT05882175. Inclusion in this directory is not an endorsement.